Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08 Agosto 2024 - 7:00AM
Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical
drug development company focused on advancing novel therapeutics
targeting degenerative retinal diseases that have significant unmet
medical needs, today announced that Dr. Nathan Mata, Chief
Scientific Officer of Belite Bio, will present a corporate update
at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
A webcast of the presentation will be available on Thursday,
August 15, 2024, at 7:00 am ET under the "Events" tab on the
investor relations section of the Belite Bio website at:
https://investors.belitebio.com/presentations-events/events. The
replay will be archived for 90 days following the presentation
date.
About Belite Bio Belite Bio is a
clinical-stage biopharmaceutical drug development company focused
on advancing novel therapeutics targeting degenerative retinal
diseases that have significant unmet medical needs, such as
Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in
advanced dry age-related macular degeneration (AMD), in addition to
specific metabolic diseases. Belite’s lead candidate, Tinlarebant,
an oral therapy intended to reduce the accumulation of toxins in
the eye, is currently being evaluated in a Phase 3 study (DRAGON)
and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and
a Phase 3 study (PHOENIX) in subjects with GA. For more
information, follow us on Twitter, Instagram, LinkedIn, and
Facebook or visit us at www.belitebio.com.
Media Relations Contact:Jennifer
Wuir@belitebio.com
Investor Relations Contact:Julie
Fallonbelite@argotpartners.com
Belite Bio (NASDAQ:BLTE)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Belite Bio (NASDAQ:BLTE)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024